Company intelligence / Profile preview

Epitopoietic Research Corporation

Ownership: Private
Development stage: Other

Overview

ERC's lead product ERC1671 (Gliovac/Sitoiganap) is in clinical development for glioblastoma multiforme. The company has provided treatment under the US Federal Right-to-try law in 2019. Their unique vaccine approach uses both patient's own tumor cells (autologous) and cells from other individuals (allogeneic) to trigger immune responses.

Therapeutic areas: OncologyInfectious Diseases
Modalities: Therapeutic vaccinesCell-based immunotherapy
Industry: Biotech

Beyond the preview

Go deeper on Epitopoietic Research Corporation.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Epitopoietic Research Corporation.